Bristol-Myers Squibb

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BMY and other ETFs, options, and stocks.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

89.61B

Market cap89.61B

Price-Earnings ratio

-14.26

Price-Earnings ratio-14.26

Dividend yield

5.29%

Dividend yield5.29%

Average volume

16.81M

Average volume16.81M

High today

$44.40

High today$44.40

Low today

$44.40

Low today$44.40

Open price

$43.94

Open price$43.94

Volume

4.69K

Volume4.69K

52 Week high

$69.10

52 Week high$69.10

52 Week low

$43.73

52 Week low$43.73

BMY News

Simply Wall St 1d

Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Bristol-Myers Squibb ( ) First Quarter 2024 Results Key Financial Results Revenue: US$11.9b (up 4.7% from 1Q 2023). Net loss: US$11.9b (down from US$2.26b pr...

Benzinga 2d

A Closer Look at Bristol-Myers Squibb's Options Market Dynamics - Bristol-Myers Squibb - Benzinga

Loading... Loading... Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb B...

Benzinga 3d

How Is The Market Feeling About Bristol-Myers Squibb? - Bristol-Myers Squibb - Benzinga

Loading... Loading... Bristol-Myers Squibb's BMY short percent of float has fallen 5.98% since its last report. The company recently reported that it has 35.12...

Analyst ratings

71%

of 28 ratings

Buy

25%

Hold

71.4%

Sell

3.6%

More BMY News

Benzinga 6d

Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights - Bristol-Myers Squibb - Benzinga

Loading... Loading... 4 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions fro...

Quartz 7d

Major drugmakers are bracing to lose their most lucrative patents this decade

Pharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug patents to expire in the next few years. Both companies reported...

Benzinga 7d

Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions

Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter r...

TipRanks 7d

Massive Job Cuts Send Bristol-Myers Squibb Stock Into Tailspin - TipRanks.com - TipRanks

Normally, planned layoffs are a good thing for a stock. Shares go up as companies cut costs and demonstrate they have the fortitude to make the tough calls. Whi...

Yahoo Finance 7d

Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat - Yahoo Finance

Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the y...

The Wall Street Journal 7d

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporti...

Seeking Alpha 7d

Bristol-Myers to cut 2,200 jobs as part of $1.5B cost saving plan

With its Q1 2024 results on Thursday, Bristol-Myers Squibb (NYSE:BMY) announced plans to lay off 2,200 employees this year as part of a cost-cutting initiative...